Axsome Therapeutics Inc [AXSM] stock is trading at $174.14, down -1.62%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AXSM shares have gain 3.93% over the last week, with a monthly amount glided 19.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on January 08, 2026, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $204 for it. Previously, B. Riley Securities started tracking the stock with Buy rating on October 01, 2025, and set its price target to $179. Oppenheimer initiated its recommendation with a Outperform and recommended $185 as its price target on June 03, 2025. Jefferies started tracking with a Buy rating for this stock on April 07, 2025, and assigned it a price target of $200. In a note dated February 11, 2025, Deutsche Bank initiated an Buy rating and provided a target price of $176 on this stock.
Axsome Therapeutics Inc [AXSM] stock has fluctuated between $86.07 and $184.40 over the past year. Currently, Wall Street analysts expect the stock to reach $211.9 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $174.14 at the most recent close of the market. An investor can expect a potential return of 21.68% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 561.26M for the trailing twelve months, which represents a growth of 63.22%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.38%, Pretax Profit Margin comes in at -0.41%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -3.57 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Axsome Therapeutics Inc’s Current Ratio is 1.57. In addition, the Quick Ratio stands at 1.50 and the Cash Ratio stands at 0.9. Considering the valuation of this stock, the price to sales ratio is 15.64, the price to book ratio is 118.82.
Transactions by insiders
Recent insider trading involved TABUTEAU HERRIOT, Chief Executive Officer, that happened on Jan 05 ’26 when 78703.0 shares were sold. Chief Executive Officer, TABUTEAU HERRIOT completed a deal on Jan 07 ’26 to sell 31261.0 shares. Meanwhile, Chief Executive Officer TABUTEAU HERRIOT sold 29450.0 shares on Jan 06 ’26.
